Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from LTR Pharma Limited ( (AU:LTP) ) is now available.
LTR Pharma Limited has announced significant milestones in its December 2024 Quarterly Activities Report, showcasing its achievements in research, development, and strategic partnerships. The company highlighted the final clinical data of its SPONTAN® nasal spray, demonstrating a 470% faster absorption rate compared to oral tablets, and a strong safety profile, which positions it as a groundbreaking solution for erectile dysfunction. The company also launched an online telehealth platform ahead of schedule, secured a joint venture with Restorative Sexual Health Clinic, and established a distribution agreement with Symbion. Additionally, LTR Pharma completed a A$25 million capital raise to bolster its financial position, enabling continued investment in U.S. commercial preparations and online platform development.
More about LTR Pharma Limited
LTR Pharma Limited is a company specializing in men’s health, focusing on the clinical development and commercialization of SPONTAN®, an innovative nasal spray treatment for erectile dysfunction.
YTD Price Performance: -1.23%
Average Trading Volume: 673,132
Technical Sentiment Consensus Rating: Strong Buy
For detailed information about LTP stock, go to TipRanks’ Stock Analysis page.
